Clinical Observation Of Low Molecular Weight Heparin Combined With Chemotherapy For Non-small Cell Lung Cancer

Objective:To evaluate the applied value of low molecular weight heparin(LMWH)combined with chemotherapy in the treatment of non-small cell lung cancer.Methods:We collected a total of 115 patients with non-small cell lung cancer from January 2014 to March 2017;We through outpatient visits and telephone interviews to get survival time;The samples were randomly divided into control group and observation group,and the sex,age,tumor type,stage,chemotherapy regimens for hierarchical analysis;The differences in the coagulation function indexes and the changes of platelets during the chemotherapy were compared between the two groups.Result:1.The median survival time in the observation group was longer than that in the control group,and the difference was not statistically significant(P=0.054>0.05).2.For the stratified analysis of gender,the median survival time in the observation group for males was longer than that in the control group,with statistically significant difference(P=0.022<0.05).The median survival time in the observation group for females was longer than that of the control group,without statistically significant difference(P=0.254>0.05).3.Stratified analysis of age groups showed that the median survival time in the observation group was longer than that in the control group in the youth group,and the difference was not statistically significant(P=0.226>0.05).In the midlife group,the median survival time in the observation group was longer than that in the control group,without statistically significant difference(P=0.333>0.05).In the agedness group,the median survival in the observation group was longer than that in the control group,with statistically significant difference(P=0.022<0.05).4.For the stratified analysis of Lung cancer staging,in the?B,?A and?B,The median survival time in the observation group was longer than that of the control group,without statistically significant difference(P>0.05).5.For the stratified analysis of tumor types,in squamous cell carcinoma,the median survival time in the observation group was longer than that in the control group,with statistically significant difference(P=0.007<0.05),In adenocarcinoma,The median survival time in the observation group was longer than that of the control group,without statistically significant difference(P>0.05).6.chemotherapy regimens analysis,In cisplatin+gemcitabine chemotherapy scheme,the median survival time in the observation group was longer than that in the control group,with statistically significant difference(P=0.034<0.05);in the cisplatin+peimecloxacil chemotherapy regimen,The median survival time in the observation group was longer than that of the control group,without statistically significant difference(P=0.884>0.05).7.There was no significant difference in the change of coagulation function index between the two groups(P>0.05).By Mann-Whitney test,the platelet decrease degree after chemotherapy in the observation group(median-17.00×10~9/L),and the thrombocytopenia was lower in the control group(median-38.50×10~9/L),with statistically significant difference(P=0.010<0.05).Conclusion:LMWH is a drug with low bleeding risk,little effect on coagulation function,and high safety.The LMWH combined with chemotherapy in the treatment of patients can improve the survival time of patients with non-small cell lung cancer.